Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis
Status:
Terminated
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test a novel strategy to prevent the clinical problem of
secondary autoimmunity following alemtuzumab treatment of multiple sclerosis.
The hypothesis is that autoimmunity after alemtuzumab can be prevented by giving a drug that
promotes thymic T cell regeneration (Palifermin, Kepivance®).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust